Ocrelizumab in Relapsing-Remitting and Progressive Multiple Sclerosis
Ocrelizumab was found to be effective and safe therapy in relapsing-remitting, primary-progressive and secondary-progressive multiple sclerosis patients. Performed on 153 patients (mean age: 41.9 years; 60% females; mean EDSS: 3.5), this study provided first real-world effectiveness and safety data and the possible predictors of treatment response. After 2 years, percentage disability worsening-free patients were 90.5%, […]